A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 16 Feb 2026
At a glance
- Drugs Icotrokinra (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms ANTHEM-UC
- Sponsors Janssen Research & Development; Janssen-Cilag
Most Recent Events
- 13 Feb 2026 Status changed from active, no longer recruiting to completed.
- 27 Oct 2025 According to Johnson and Johnson media release, Based on results from the Phase 2b ANTHEM-UC study, the company have initiated the phase 3 ICONIC-UC and ICONIC-CD Phase 2b/3 studies.
- 27 Oct 2025 According to Johnson and Johnson media release, data from this trial will be presented at the 2025 American College of Gastroenterology Annual Scientific Meeting (ACG).